dHAND Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB-203580 inhibits dHAND indirectly by targeting the p38 MAPK pathway. As a p38 MAPK inhibitor, SB-203580 interferes with the phosphorylation cascade that regulates dHAND activity, leading to its inhibition. This highlights the role of p38 MAPK signaling in modulating dHAND expression and function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits dHAND indirectly by targeting the JNK pathway. As a JNK inhibitor, SP600125 disrupts the phosphorylation events that regulate dHAND activity, resulting in its inhibition. This underscores the importance of JNK signaling in modulating dHAND expression and function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits dHAND indirectly by targeting the ERK signaling pathway. As an ERK inhibitor, U0126 disrupts the phosphorylation cascade that regulates dHAND activity, leading to its inhibition. This emphasizes the role of ERK signaling in modulating dHAND expression and function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits dHAND indirectly by targeting the PI3K/Akt signaling pathway. As a PI3K inhibitor, Wortmannin interferes with the activation of Akt, a downstream effector of PI3K, ultimately disrupting the signaling events that regulate dHAND activity and leading to its inhibition. This elucidates the connection between PI3K/Akt signaling and dHAND modulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits dHAND indirectly by targeting the PI3K/Akt signaling pathway. As a PI3K inhibitor, LY294002 interferes with the activation of Akt, disrupting the signaling events that regulate dHAND activity and leading to its inhibition. This highlights the intricate interplay between PI3K/Akt signaling and the modulation of dHAND expression and function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits dHAND indirectly by targeting the mTOR signaling pathway. As an mTOR inhibitor, Rapamycin disrupts the downstream signaling events that regulate dHAND activity, leading to its inhibition. This underscores the role of mTOR signaling in modulating dHAND expression and function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits dHAND indirectly by targeting the MEK/ERK signaling pathway. As a MEK inhibitor, PD98059 disrupts the phosphorylation cascade that regulates dHAND activity, resulting in its inhibition. This emphasizes the importance of MEK/ERK signaling in modulating dHAND expression and function. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB-216763 inhibits dHAND indirectly by targeting glycogen synthase kinase-3 beta (GSK-3β). As a GSK-3β inhibitor, SB-216763 interferes with the downstream signaling events that regulate dHAND activity, leading to its inhibition. This emphasizes the connection between GSK-3β signaling and the modulation of dHAND expression and function. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
Akt Inhibitor VIII inhibits dHAND indirectly by targeting Akt, a downstream effector of the PI3K/Akt signaling pathway. By inhibiting Akt activation, Akt Inhibitor VIII disrupts the signaling events that regulate dHAND activity, leading to its inhibition. This elucidates the crucial role of Akt signaling in modulating dHAND expression and function. | ||||||